# China Personalized Medicine Market > China Personalized Medicine Market Research Report By Product Outlook (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness), By Application Outlook (Oncology, CNS, Immunology, Respiratory, Others) and By End-User Outlook (Hospitals, Diagnostic Centers, Research Academic Institutes, Others-Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.01% - **2024:** $ 44.75 Billion - **2025:** $ 47.44 Billion - **2035:** $ 85 Billion - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK(GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) **Report ID:** MRFR/HC/43637-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-personalized-medicine-market-45317 --- ## Market Summary ## **China Personalized Medicine Market Overview** As per MRFR analysis, the China Personalized Medicine Market Size was estimated at 41.74 (USD Billion) in 2023.The China Personalized Medicine Market is expected to grow from 44.75(USD Billion) in 2024 to 95.8 (USD Billion) by 2035. The China Personalized Medicine Market CAGR (growth rate) is expected to be around 7.165% during the forecast period (2025-2035). ### **Key China Personalized Medicine Market Trends Highlighted** Innovations in biotechnology and genetics are driving significant trends in the Chinese personalized medicine market. The Chinese government has supported programs that advance customized medicine by making large investments in biotechnology research and healthcare. China is becoming a center for research and development in this area due to the acceleration of innovation brought about by increased cooperation between the public and commercial sectors. One of the main forces behind personalized medicine is the increasing incidence of chronic illnesses like diabetes and cancer in China, which is leading to a move toward therapies based on each patient's unique genetic profile. Furthermore, a data-driven approach to patient care is being promoted by the ability to examine enormous volumes of health data thanks to developments in artificial intelligence and data analytics. Since hospitals and research organizations want to incorporate genomic testing into their routine care procedures, there are opportunities for integrating genomic data into clinical practice. This change has the potential to greatly enhance patient outcomes and more effectively customize treatment regimens. Additionally, recent trends show that the public is becoming more aware of personalized medicine and its advantages, which is driving up patient demand for individualized treatment regimens. Furthermore, the use of cutting-edge technologies like gene editing and CRISPR, which are essential to the creation of customized treatments, is on the rise in the Chinese market. The Chinese government's supporting regulatory framework, which aims to guarantee the safety and effectiveness of personalized medicine solutions and so provide a favorable climate for growth and innovation in the sector, highlights these tendencies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **China Personalized Medicine Market Drivers** ### **Rising Incidence of Chronic Diseases** The growing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer in China is a significant driver for the China Personalized Medicine Market. According to the National Health Commission of China, the number of people living with diabetes has surged to over 120 million, highlighting a critical need for personalized treatment options. Furthermore, the incidence of cancer is projected to reach 4.6 million new cases annually by 2025, based on estimates from the Chinese National Cancer Center. This increase in chronic disease cases emphasizes the demand for tailored therapeutic approaches that address individual patient profiles, ultimately fueling the personalized medicine sector. Institutions like the Chinese Center for Disease Control and Prevention are actively supporting initiatives that promote personalized treatment plans, which aligns with the national goal of enhancing healthcare outcomes through technology and innovation. As healthcare systems aim to adopt more personalized modalities, the growth of the China Personalized Medicine Market will see significant acceleration driven by these factors. ### **Government Investment in Biotechnology** The Chinese government has made substantial investments in biotechnology and healthcare innovation, which serves as a key driver in the China Personalized Medicine Market. The Government of China has launched the 'Made in China 2025' initiative and earmarked billions for sectors, including biotechnology, aiming to boost its global position in therapeutic development. This initiative aligns with China’s commitment to improving healthcare access and outcomes through cutting-edge technologies. With state support, numerous biotech startups and established companies are undergoing rapid development, fostering an environment ripe for advancements in personalized medicine. For instance, a report from the Ministry of Science and Technology reveals that biotechnology funding has surpassed 200 billion CNY annually, establishing a robust ecosystem for R, which is expected to proliferate personalized treatment solutions within the next decade. ### **Increasing Focus on Genomic Research** Genomic research is rapidly gaining momentum in China, bolstered by the country’s investment in genomics and its applications within personalized medicine. The Chinese government is funding numerous genomic projects, such as the 100,000 Genomes Project, with an aim to harness genomic data in developing tailored therapies for various diseases. By 2025, it is projected that China will have sequenced more than 200 million whole genomes, driving the personalized medicine initiatives effectively. The rising number of research papers being published by leading Chinese academic and research institutions showcases advancements in genetic research which is crucial for tailoring treatments to individual genetic profiles, indicating a strong growth trajectory for the China Personalized Medicine Market. Moreover, organizations like the Chinese Academy of Sciences are at the forefront, ensuring that China’s genomic research not only contributes to scientific knowledge but also translates into practical healthcare applications. ## **China Personalized Medicine Market Segment Insights** ### **Personalized Medicine Market Product Outlook Insights** The China Personalized Medicine Market has shown a commendable trajectory, with diverse product segments contributing to its growth and relevance. Within this market, personalized medicine diagnostics play a crucial role, providing tailored assessments that lead to improved patient outcomes. Diagnostics powered by genomic data and advanced analytics facilitate early disease detection and enable healthcare professionals to design specific treatment plans that cater to individual patient needs. Personalized medicine therapeutics is another significant area, where drug therapies are developed based on particular genetic and molecular profiles, thus enhancing efficacy and minimizing side effects for patients. Furthermore, personalized medical care emphasizes an individualized approach to healthcare delivery, allowing for enhanced patient engagement and satisfaction. In addition to these categories, personalized nutrition and wellness are gaining traction as consumers increasingly seek diet and health programs tailored to their genetic backgrounds and lifestyle choices. The growing awareness of chronic diseases in China and the increase in precision medicine initiatives are pivotal drivers for these segments. Market statistics reveal a burgeoning interest in preventive healthcare and lifestyle disease management, suggesting that personalized medicine approaches have great potential in addressing diverse health issues faced by the Chinese population. Collectively, these aspects underscore the dynamic nature of the China Personalized Medicine Market and its increasing importance in responding to a range of healthcare challenges. As the sector continues to evolve, innovations in technology and greater integration of data analytics will likely foster further advancements in personalized medicine applications across these product categories. Consequently, the combination of high demand for specialized treatment options and a robust healthcare infrastructure positions China as a key player in the regional and global landscape of personalized medicine. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Personalized Medicine Market Application Outlook Insights** The Application Outlook segment of the China Personalized Medicine Market reflects significant advancements across various therapeutic areas, notably Oncology, CNS, Immunology, and Respiratory conditions, among others. Oncology is a prominent focus due to the rising cancer prevalence in China, where personalized treatment strategies, including targeted therapies, are becoming essential for improving patient outcomes. The CNS segment is crucial as neurodegenerative diseases continue to pose a substantial healthcare challenge, prompting the development of tailored therapies that address specific molecular pathways. In [Immunology](../../../reports/immunology-market-30261), the need for personalized approaches is driven by an increasing number of autoimmune disorders, requiring innovative treatments that consider individual responses to medication. The Respiratory segment, particularly in addressing conditions such as asthma and chronic obstructive pulmonary disease, benefits from personalized medicine, as it allows for tailored management based on genetic, environmental, and lifestyle factors. Overall, the rich diversity within the China Personalized Medicine Market segmentation is poised to drive substantial growth, supported by ongoing research and advancements in biomedicine. The market trends signal a shift towards more individualized healthcare solutions that effectively cater to the unique needs of patients within the Chinese healthcare system. ### **Personalized Medicine Market End-User Outlook Insights** The China Personalized Medicine Market is significantly influenced by its End-User Outlook, which encompasses various crucial sectors such as Hospitals, Diagnostic Centers, Research Academic Institutes, and Others. Hospitals are critical protagonists in the delivery of personalized medicine due to their capacity for advanced treatment and patient management. Diagnostic Centers play a pivotal role by providing essential testing and analysis services to enable precision medicine tailored to individual characteristics. Research Academic Institutes contribute vital insights and developments, driving innovation in personalized therapy practices and technologies, which has seen heightened interest from the Chinese government in boosting healthcare advancements. Furthermore, the 'Others' category includes a range of alternative healthcare providers that offer specialized services that complement traditional healthcare approaches. The demand for personalized medicine is being propelled by an increasing prevalence of chronic diseases and a rising aging population, necessitating more tailored healthcare solutions. With the potential for significant breakthroughs in patient treatment and the promising scope for development, the End-User Outlook within the China Personalized Medicine Market is expected to play a foundational role in shaping the industry's evolution in the coming years. ## **China Personalized Medicine Market Key Players and Competitive Insights** The China Personalized Medicine Market is rapidly evolving, characterized by an increasing focus on tailored healthcare solutions that meet individual patient needs. This market has seen significant growth due to advancements in technology, particularly in genomics and biotechnology, enabling healthcare providers to develop targeted therapies that improve treatment outcomes. Various stakeholders, including pharmaceutical companies, biotechnology firms, and healthcare providers, are actively competing to establish their presence in this expanding market. The competitive landscape is marked by innovation and collaboration as companies seek to leverage their strengths in research and development, clinical trials, and regulatory compliance to gain a competitive edge. Furthermore, the burgeoning demand for personalized healthcare solutions has attracted both local and international players, all striving to carve out their share of this lucrative market. Guangzhou Deyou Technology has established itself as a strong competitor within the China Personalized Medicine Market. The company leverages its expertise in genomics and data analytics to provide advanced solutions directly impacting patient outcomes. With a solid focus on research and development, Guangzhou Deyou Technology has developed a range of personalized diagnostic tools that cater to specific health conditions prevalent in the region. The company's innovative approach stems from a deep understanding of local healthcare needs, allowing it to meet the demands of both healthcare providers and patients effectively. Additionally, Guangzhou Deyou Technology has built robust partnerships with various medical institutions, enhancing its market presence and facilitating rapid adoption of its personalized medicine solutions throughout China. Such strengths position the company favorably as it navigates this dynamic and competitive environment. Roche plays a pivotal role in the China Personalized Medicine Market and is recognized for its commitment to precision healthcare through innovative products and services. The company’s portfolio boasts an array of targeted therapies and diagnostic tools that cater to a diverse range of diseases, particularly in oncology, where tailored treatment regimens are crucial for patient outcomes. Roche has solidified its market presence in China with a strategic focus on local needs, engaging in partnerships with healthcare providers to enhance clinical decision-making. The company’s strengths lie in its extensive research capabilities, which drive the development of cutting-edge therapies, as well as its efficient production processes. Roche has also actively pursued mergers and acquisitions to expand its footprint and enhance its technology offerings in the personalized medicine domain. This proactive approach has strengthened its capabilities in delivering personalized treatments, ensuring that Roche remains a key player in shaping the future of personalized healthcare in China. **Key Companies in the China Personalized Medicine Market Include** - Guangzhou Deyou Technology - Roche - Sanofi - Wuxi Apptec - [Merck](https://www.merckgroup.com/en/sustainability/sustainables/personalized-medicine.html) - Novartis - Amgen - Pfizer - Zhejiang Hisun Pharmaceutical - GSK - Illumina - Boehringer Ingelheim - Beijing Jinshan Science and Technology - AbbVie - Takeda ## **China Personalized Medicine****Market****Developments** Recent developments in the China Personalized Medicine Market indicate a robust growth trajectory fueled by advancements in genomics and biotechnology. Companies like Guangzhou Deyou Technology and Zhejiang Hisun Pharmaceutical continue to innovate in precision therapies, while Roche and Novartis explore collaborations to enhance their drug pipelines. Notably, in August 2023, AbbVie announced an investment in local biotech firms focusing on personalized treatment solutions in oncology. In September 2023, Merck strengthened its presence by acquiring a stake in a Chinese gene sequencing company, enhancing its capabilities in targeted therapies. Furthermore, Wuxi Apptec is expanding its manufacturing facilities to support the growing demand for personalized medicine. The market's growth is underscored by government support and funding initiatives, bolstering research and development capabilities. The Chinese government aims to sustain momentum in personalized healthcare, along with initiatives to enhance regulatory frameworks, ensuring safety and efficacy in new therapies. Over the past two years, the sector has gained momentum, with investment surging and strategic partnerships emerging to drive innovation, exemplified by significant collaborations and funding drives between local companies and global giants like Pfizer and GSK. ## **China Personalized Medicine Market Segmentation Insights** ### **China Personalized Medicine Market****Product Outlook** ### **China Personalized Medicine Market****Application Outlook** ### **China Personalized Medicine Market****End-User Outlook** - Hospitals - Diagnostic Centers - Research Academic Institutes - Others - Beta - Beta feature ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at promoting innovation in healthcare are playing a crucial role in the growth of the personalized medicine market. In China, the government has launched several funding programs to support research in genomics and biotechnology. For instance, the 13th Five-Year Plan emphasizes the development of precision medicine, allocating substantial resources to enhance research capabilities. This strategic focus is expected to boost the personalized medicine market, with projections indicating a market value of approximately $20 billion by 2025. Such initiatives not only encourage public-private partnerships but also stimulate the development of new therapies and diagnostic tools tailored to individual patient needs. The commitment of the Chinese government to advancing personalized medicine is likely to create a conducive environment for innovation and growth in this sector. ### Advancements in Genomic Technologies The rapid advancements in genomic technologies are significantly influencing the personalized medicine market. Innovations such as next-generation sequencing (NGS) and CRISPR gene editing are enabling more precise and efficient genetic analysis. In China, the NGS market alone is expected to grow at a CAGR of over 20% through 2025, driven by increased investments in research and development. These technologies facilitate the identification of genetic markers associated with diseases, allowing for the development of tailored therapies. As a result, healthcare providers are increasingly adopting these technologies to enhance diagnostic accuracy and treatment efficacy, thereby fostering growth in the personalized medicine market. The ability to analyze vast amounts of genetic data is likely to lead to breakthroughs in understanding complex diseases, further solidifying the role of personalized medicine in the healthcare landscape. ### Rising Demand for Targeted Therapies The increasing prevalence of chronic diseases in China is driving the demand for targeted therapies. These therapies are a cornerstone of the personalized medicine market. As healthcare providers seek more effective treatment options, the focus on therapies tailored to individual genetic profiles is intensifying. Reports indicate that the market for targeted therapies in China is projected to reach approximately $30 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 15%. This trend suggests that healthcare stakeholders are prioritizing personalized approaches to improve patient outcomes, thereby propelling the personalized medicine market forward. Furthermore, the integration of genomic data into clinical practice is likely to enhance the efficacy of treatments, making personalized medicine an essential component of modern healthcare in China. ### Increasing Investment in Biopharmaceuticals The surge in investment in biopharmaceuticals is significantly impacting the personalized medicine market. In China, biopharmaceutical companies are increasingly focusing on developing personalized therapies, driven by the need for more effective treatment options. Reports suggest that the biopharmaceutical market in China is expected to exceed $100 billion by 2025, with a substantial portion allocated to personalized medicine initiatives. This influx of capital is facilitating the research and development of innovative therapies that cater to specific patient populations. As investors recognize the potential of personalized medicine to improve treatment outcomes, the market is likely to experience accelerated growth. The collaboration between biopharmaceutical firms and research institutions is also expected to enhance the development of targeted therapies, further solidifying the position of personalized medicine in the healthcare ecosystem. ### Growing Collaborations Between Academia and Industry The increasing collaborations between academic institutions and industry players are fostering innovation in the personalized medicine market. In China, partnerships between universities and biotechnology firms are becoming more prevalent, aimed at translating research findings into practical applications. These collaborations are essential for advancing the development of personalized therapies and diagnostics. For instance, joint research initiatives are focusing on identifying genetic biomarkers that can guide treatment decisions. The personalized medicine market is likely to benefit from these synergies, as they facilitate the sharing of knowledge and resources. Moreover, such partnerships can accelerate the commercialization of new technologies, potentially leading to a market growth rate of around 12% annually. The collaborative efforts are expected to enhance the overall landscape of personalized medicine, making it a pivotal area of focus for future healthcare advancements. ## Future Outlook The [Personalized Medicine Market](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) in China is projected to grow at a 6.01% CAGR from 2025 to 2035, driven by advancements in genomics, technology integration, and increasing healthcare demand. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Investment in biobanking for personalized drug development and research. By 2035, the personalized medicine market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Personalized Medicine Diagnostics (Largest) vs. Personalized Medicine Therapeutics (Fastest-Growing) In the China personalized medicine market, the segment of Personalized Medicine Diagnostics holds the largest share, reflecting its significance in patient assessment and tailored treatment strategies. This segment leads due to the increasing adoption of genomic testing and biomarker-driven diagnostics, which facilitate more precise treatment plans and enhance patient outcomes. On the other hand, Personalized Medicine Therapeutics is recognized as the fastest-growing segment, fueled by advancements in targeted therapies that cater specifically to genetic profiles, leading to improved efficacy and reduced side effects. The growth trends in these segments are bolstered by a rising prevalence of chronic diseases and genetic disorders among the population in China. Furthermore, government initiatives promoting research and development in personalized medicine are contributing significantly to innovation and market expansion. The growing demand for individualized healthcare solutions coupled with enhanced patient awareness about personalized therapies is expected to drive the momentum in both diagnostics and therapeutics, setting a dynamic pace for the overall market. Personalized Medicine Diagnostics (Dominant) vs. Personalized Medicine Therapeutics (Emerging) Personalized Medicine Diagnostics stands out as a dominant force within the China personalized medicine market, characterized by a robust infrastructure for testing and analysis including advanced genomic sequencing technologies. Its established position is complemented by increasing investments in clinical laboratories and diagnostic companies, facilitating a wide array of tests that cater to specific patient needs. Conversely, Personalized Medicine Therapeutics is an emerging segment that is rapidly gaining traction, emphasizing the development of drugs tailored to individual genetic profiles. Its growth is propelled by continuous research and development activities aimed at discovering unique therapeutic solutions, thus transforming the treatment landscape and offering patients more personalized and effective health care options. ### By Application: Oncology (Largest) vs. CNS (Fastest-Growing) In the China personalized medicine market, the oncology segment holds the largest market share, showcasing its significance in driving advancements in targeted therapies and precision treatments. Meanwhile, the CNS segment is gaining traction, emerging as the fastest-growing area, fueled by increasing awareness and demand for innovative therapeutic approaches addressing neurological disorders. Growth trends within these segments are largely influenced by escalating investments in research and development, coupled with a robust regulatory framework encouraging tailored therapies. The increasing prevalence of chronic diseases, particularly cancer and CNS disorders, propels demand for personalized treatment options, making these segments pivotal in shaping the future landscape of healthcare in the region. Oncology (Dominant) vs. CNS (Emerging) Oncology remains the dominant segment in personalized medicine, characterized by extensive research efforts aimed at developing tailored therapies to combat various types of cancer. This segment benefits from strong pharmaceutical initiatives and collaborative projects among biotech firms and healthcare institutions. In contrast, the CNS segment is recognized as an emerging area, focusing on personalized approaches for neurological diseases such as Alzheimer's and Parkinson's. This segment is witnessing rapid advancements, with innovative treatments and biomarker developments aimed at enhancing patient outcomes. The growing emphasis on addressing mental health and neurodegenerative diseases positions the CNS segment as a critical focus area for future investment and research. ### By End-User: Hospitals (Largest) vs. Research & Academic Institutes (Fastest-Growing) In the China personalized medicine market, Hospitals hold a significant share, being the largest end-user segment. They are pivotal in adopting advanced personalized therapies due to their established infrastructure and comprehensive patient care capabilities. Diagnostic Centers and Research & Academic Institutes also play critical roles, albeit with smaller market shares. The 'Others' category encompasses various smaller yet essential sectors contributing to the overall market dynamics. Growth trends within the end-user segment indicate a rising demand for personalized medicine in Research & Academic Institutes, which is currently the fastest-growing segment. This growth is driven by increased investment in research and development, collaboration with hospitals for clinical trials, and the need for innovative treatment options. Hospitals continue to expand personalized medicine services to improve patient outcomes as healthcare systems evolve toward more tailored approaches. Hospitals (Dominant) vs. Research & Academic Institutes (Emerging) Hospitals dominate the China personalized medicine market as they have the largest share, characterized by their ability to integrate personalized therapies into routine patient care effectively. They are equipped with advanced technologies and skilled professionals, making them central to the adoption of these innovative treatments. Conversely, Research & Academic Institutes are emerging rapidly as key players, with a focus on research and innovation. Their role in fostering collaborations with hospitals and biotech firms places them at the forefront of developing new therapies. This dynamic combination of established hospitals and emerging research institutions fosters a robust ecosystem for personalized medicine, driving advancements and improving treatment outcomes. ## Competitive Benchmarking The personalized medicine market in China is characterized by a dynamic competitive landscape, driven by rapid advancements in genomics, biotechnology, and data analytics. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Roche (CH) focuses on integrating diagnostics with therapeutics, enhancing patient outcomes through tailored treatment plans. Meanwhile, Thermo Fisher Scientific (US) emphasizes its commitment to expanding its portfolio of genomic solutions, which is crucial for personalized medicine applications. Illumina (US) continues to lead in sequencing technologies, positioning itself as a critical enabler of precision medicine through its cutting-edge platforms. Collectively, these strategies foster a competitive environment that prioritizes innovation and collaboration, ultimately enhancing the efficacy of personalized treatments. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to meet the growing demand for personalized medicine in China. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This collective influence of key players not only drives competition but also encourages the sharing of knowledge and resources, which is essential for advancing personalized medicine solutions. In October 2025, Roche (CH) announced a strategic partnership with a leading Chinese biotech firm to develop a new class of targeted therapies aimed at specific genetic markers prevalent in the Chinese population. This collaboration is significant as it underscores Roche's commitment to tailoring its offerings to local needs, thereby enhancing its market presence and aligning with the growing emphasis on personalized healthcare solutions in China. In September 2025, Illumina (US) launched a new genomic sequencing platform specifically designed for the Asian market, which is expected to significantly reduce the time and cost associated with genetic testing. This move is pivotal as it not only strengthens Illumina's foothold in the region but also addresses the increasing demand for rapid and affordable genomic solutions, thereby enhancing patient access to personalized medicine. In August 2025, Thermo Fisher Scientific (US) expanded its operations in China by establishing a new manufacturing facility dedicated to producing advanced diagnostic tools. This expansion is strategically important as it allows Thermo Fisher to better serve the local market while also reducing lead times and costs associated with importing products. Such initiatives reflect a broader trend of companies investing in local capabilities to enhance their competitive edge. As of November 2025, current trends in the personalized medicine market include a strong focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift is likely to redefine how companies position themselves in the market, emphasizing the importance of delivering high-quality, personalized healthcare solutions. ## Recent News & Developments Recent developments in the China Personalized Medicine Market indicate a robust growth trajectory fueled by advancements in genomics and biotechnology. Companies like Guangzhou Deyou Technology and Zhejiang Hisun Pharmaceutical continue to innovate in precision therapies, while Roche and Novartis explore collaborations to enhance their drug pipelines. Notably, in August 2023, AbbVie announced an investment in local biotech firms focusing on personalized treatment solutions in oncology. In September 2023, Merck strengthened its presence by acquiring a stake in a Chinese gene sequencing company, enhancing its capabilities in targeted therapies. Furthermore, Wuxi Apptec is expanding its manufacturing facilities to support the growing demand for personalized medicine. The market's growth is underscored by government support and funding initiatives, bolstering research and development capabilities. The Chinese government aims to sustain momentum in personalized healthcare, along with initiatives to enhance regulatory frameworks, ensuring safety and efficacy in new therapies. Over the past two years, the sector has gained momentum, with investment surging and strategic partnerships emerging to drive innovation, exemplified by significant collaborations and funding drives between local companies and global giants like Pfizer and GSK. ## Report Scope | MARKET SIZE 2024 | 44.75(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 47.44(USD Billion) | | MARKET SIZE 2035 | 85.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.01% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Bristol-Myers Squibb (US), Pfizer (US), Merck KGaA (DE), Amgen (US) | | Segments Covered | Product, Application, End-User | | Key Market Opportunities | Integration of artificial intelligence in personalized medicine enhances treatment precision and patient outcomes. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the personalized medicine market. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the personalized medicine market in China as of 2024?** A: The personalized medicine market in China was valued at 44.75 $ Billion in 2024. **Q: What is the projected market size for personalized medicine in China by 2035?** A: The market is projected to reach 85.0 $ Billion by 2035. **Q: What is the expected CAGR for the personalized medicine market in China during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 6.01 %. **Q: Which segments are included in the personalized medicine market in China?** A: The market includes segments such as Personalized Medicine Diagnostics, Therapeutics, Medical Care, and Nutrition and Wellness. **Q: What was the valuation of the Personalized Medicine Diagnostics segment in 2024?** A: In 2024, the Personalized Medicine Diagnostics segment was valued at 8.0 $ Billion. **Q: How much is the Personalized Medicine Therapeutics segment projected to grow by 2035?** A: The Personalized Medicine Therapeutics segment is projected to grow from 20.0 $ Billion in 2024 to 40.0 $ Billion by 2035. **Q: What are the key applications of personalized medicine in China?** A: Key applications include Oncology, CNS, Immunology, and Respiratory, with Oncology valued at 15.0 $ Billion in 2024. **Q: Which end-users are driving the personalized medicine market in China?** A: End-users include Hospitals, Diagnostic Centers, and Research & Academic Institutes, with Hospitals valued at 15.0 $ Billion in 2024. **Q: Who are the leading companies in the personalized medicine market in China?** A: Key players include Roche, Thermo Fisher Scientific, Illumina, Novartis, GSK, Bristol-Myers Squibb, Pfizer, Merck KGaA, and Amgen. **Q: What is the projected growth for the Personalized Nutrition and Wellness segment by 2035?** A: The Personalized Nutrition and Wellness segment is projected to grow from 6.75 $ Billion in 2024 to 10.0 $ Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-personalized-medicine-market-45317*